Total Payments
$6,353
2024 Payments
$1,935
Companies
18
Transactions
43
Medicare Patients
1,082
Medicare Billing
$108,255
Payment Breakdown by Category
Consulting$3,275 (51.5%)
Food & Beverage$2,761 (43.5%)
Education$316.98 (5.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $3,275 | 3 | 51.5% |
| Food and Beverage | $2,761 | 36 | 43.5% |
| Education | $316.98 | 4 | 5.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $2,148 | 13 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $1,934 | 3 | $0 (2023) |
| Janssen Biotech, Inc. | $441.97 | 5 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $319.51 | 3 | $0 (2018) |
| GENZYME CORPORATION | $300.48 | 3 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $227.88 | 2 | $0 (2024) |
| Amgen Inc. | $187.16 | 2 | $0 (2022) |
| Celgene Corporation | $134.36 | 1 | $0 (2017) |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $125.00 | 1 | $0 (2024) |
| Genentech USA, Inc. | $124.99 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,935 | 8 | ABBVIE INC. ($1,359) |
| 2023 | $1,372 | 4 | Janssen Pharmaceuticals, Inc ($1,100) |
| 2022 | $1,538 | 11 | Janssen Pharmaceuticals, Inc ($834.25) |
| 2021 | $196.67 | 3 | Amgen Inc. ($87.17) |
| 2020 | $136.33 | 2 | Genentech USA, Inc. ($124.99) |
| 2019 | $417.16 | 5 | AbbVie, Inc. ($245.16) |
| 2018 | $325.50 | 4 | Janssen Scientific Affairs, LLC ($202.13) |
| 2017 | $431.53 | 6 | Celgene Corporation ($134.36) |
All Payment Transactions
43 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/02/2024 | PBG PUERTO RICO LLC | LITFULO (Drug) | Food and Beverage | In-kind items and services | $23.75 | General |
| Category: IMMUNOLOGY | ||||||
| 11/14/2024 | Lilly USA, LLC | — | Food and Beverage | Cash or cash equivalent | $118.71 | General |
| 08/22/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Odomzo (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Oncology | ||||||
| 05/23/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Immunology | ||||||
| 05/09/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $103.44 | General |
| Category: Immunology | ||||||
| 04/02/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Education | In-kind items and services | $79.99 | General |
| Category: Immunology | ||||||
| 03/05/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $1,350.00 | General |
| 02/28/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $9.36 | General |
| Category: IMMUNOLOGY | ||||||
| 08/16/2023 | AbbVie Inc. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: IMMUNOLOGY | ||||||
| 06/27/2023 | Janssen Pharmaceuticals, Inc | TREMFYA (Drug), STELARA | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| Category: Immunology | ||||||
| 06/13/2023 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $22.47 | General |
| Category: Dermatology | ||||||
| 04/26/2023 | AbbVie Inc. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/10/2022 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $124.44 | General |
| Category: Immunology | ||||||
| 10/19/2022 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $99.99 | General |
| Category: Inflammation | ||||||
| 09/14/2022 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $115.47 | General |
| Category: IMMUNOLOGY | ||||||
| 08/30/2022 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $5.21 | General |
| Category: IMMUNOLOGY | ||||||
| 06/22/2022 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $64.83 | General |
| Category: IMMUNOLOGY | ||||||
| 06/08/2022 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $90.99 | General |
| Category: IMMUNOLOGY | ||||||
| 05/25/2022 | GENZYME CORPORATION | DUPIXENT (Biological), DUPIXENT | Food and Beverage | In-kind items and services | $117.11 | General |
| Category: Immunology | ||||||
| 04/25/2022 | Janssen Pharmaceuticals, Inc | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $9.25 | General |
| Category: Immunology | ||||||
| 04/18/2022 | Janssen Biotech, Inc. | TREMFYA (Drug) | Education | In-kind items and services | $79.99 | General |
| Category: Immunology | ||||||
| 04/05/2022 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $5.88 | General |
| Category: IMMUNOLOGY | ||||||
| 01/05/2022 | Janssen Pharmaceuticals, Inc | TREMFYA (Drug) | Consulting Fee | Cash or cash equivalent | $825.00 | General |
| Category: Immunology | ||||||
| 12/02/2021 | LEO Pharma Inc. | FINACEA (Drug) | Food and Beverage | In-kind items and services | $24.50 | General |
| Category: DERMATOLOGY | ||||||
| 11/30/2021 | Janssen Biotech, Inc. | TREMFYA (Drug) | Education | In-kind items and services | $85.00 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 272 | 392 | $34,002 | $25,850 |
| 2022 | 6 | 272 | 421 | $36,442 | $27,104 |
| 2021 | 7 | 282 | 439 | $39,118 | $30,492 |
| 2020 | 6 | 256 | 467 | $33,209 | $24,809 |
Total Patients
1,082
Total Services
1,719
Medicare Billing
$108,255
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 129 | 212 | $19,254 | $14,652 | 76.1% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 48 | 55 | $6,356 | $4,983 | 78.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 35 | 35 | $3,949 | $2,931 | 74.2% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 19 | 20 | $2,067 | $1,581 | 76.5% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 27 | 31 | $2,111 | $1,495 | 70.8% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 14 | 39 | $264.42 | $207.25 | 78.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 123 | 220 | $20,317 | $15,137 | 74.5% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 49 | 58 | $6,803 | $5,284 | 77.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 32 | 32 | $3,654 | $2,527 | 69.2% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 33 | 42 | $2,905 | $2,021 | 69.6% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 21 | 23 | $2,442 | $1,918 | 78.5% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 14 | 46 | $320.62 | $216.62 | 67.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 109 | 223 | $20,688 | $16,224 | 78.4% |
| 17110 | Destruction of up to 14 skin growths | Office | 2021 | 48 | 63 | $7,363 | $5,768 | 78.3% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 42 | 42 | $4,778 | $3,665 | 76.7% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 26 | 28 | $2,997 | $2,398 | 80.0% |
| 17000 | Destruction of skin growth | Office | 2021 | 28 | 30 | $2,030 | $1,489 | 73.3% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 14 | 18 | $1,028 | $761.58 | 74.1% |
| 17003 | Destruction of 2-14 skin growths | Office | 2021 | 15 | 35 | $233.45 | $186.81 | 80.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 123 | 256 | $19,677 | $14,597 | 74.2% |
| 17110 | Destruction of up to 14 skin growths | Office | 2020 | 36 | 41 | $4,719 | $3,749 | 79.4% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 36 | 36 | $3,954 | $2,723 | 68.9% |
| 17000 | Destruction of skin growth | Office | 2020 | 26 | 34 | $2,281 | $1,722 | 75.5% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2020 | 17 | 20 | $2,061 | $1,630 | 79.1% |
| 17003 | Destruction of 2-14 skin growths | Office | 2020 | 18 | 80 | $515.94 | $387.97 | 75.2% |
About Dr. Damaris Torres Paoli, M.D
Dr. Damaris Torres Paoli, M.D is a Dermatology healthcare provider based in Rio Piedras, Puerto Rico. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1922101260.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Damaris Torres Paoli, M.D has received a total of $6,353 in payments from pharmaceutical and medical device companies, with $1,935 received in 2024. These payments were reported across 43 transactions from 18 companies. The most common payment nature is "Consulting Fee" ($3,275).
As a Medicare-enrolled provider, Torres Paoli has provided services to 1,082 Medicare beneficiaries, totaling 1,719 services with total Medicare billing of $108,255. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Rio Piedras, PR
- Active Since 09/05/2006
- Last Updated 07/08/2007
- Taxonomy Code 207N00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1922101260
Products in Payments
- TREMFYA (Drug) $2,304
- SKYRIZI (Biological) $346.03
- Otezla (Drug) $321.52
- Tremfya (Drug) $274.13
- Sotyktu (Drug) $227.88
- RINVOQ (Biological) $195.71
- DUPIXENT (Drug) $183.37
- Skyrizi (Biological) $129.28
- Odomzo (Drug) $125.00
- Erivedge (Biological) $124.99
- STELARA (Biological) $117.38
- DUPIXENT (Biological) $117.11
- Humira (Biological) $115.88
- MENACTRA (Drug) $46.13
- EUCRISA (Drug) $40.00
- EPIDUO FORTE (Drug) $29.39
- FINACEA (Drug) $24.50
- LITFULO (Drug) $23.75
- COSENTYX (Drug) $22.47
- HUMIRA (Biological) $11.34
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.